"Current CDC guidelines may miss a significant number of asymptomatic STIs among PrEP users," researchers concluded, suggesting that STI screening may be warranted at each three-monthly visit.
Research presented at CROI 2016 shows that Truvada PrEP is safe for most people, but impaired kidney function -- usually mild or moderate -- may occur in a small proportion of people on PrEP, especially if they have other risk factors.
A cardiovascular risk-scoring system known as ASCVD appears to be a better predictor of myocardial infarction (MI) among people with HIV than other risk scores, including Framingham and D:A:D, according to new research.
While the total number of gut bacteria doesn't differ between HIV-negative and HIV-positive people, the composition of the microorganisms changes with HIV infection, according to research presented at CROI 2016.
With buildings leveled by arson and systematic neglect, its population crammed into debilitated and overcrowded housing without access to basic public safety and public health services, the inescapable poverty of the Bronx provided fertile ground for...
Flu season can bring anxiety for people living with HIV and their health care providers. But do HIV-positive people have more severe symptoms of flu than people who are not living with HIV? In this interview, Christina Schofield, M.D., shares her stu...
HIV treatment as prevention has become a well-known and powerful tool in the global HIV response. In this interview, Mark Sulkowski, M.D., discusses whether a similar approach could be used in the prevention of hepatitis C.
No Difference in Neuropsychological Test Results Between Early and Delayed Treatment in START Substudy
Neuropsychological test results were similar for those who started antiretroviral therapy immediately and those who waited before starting, according to a substudy in the START study.
People randomized to begin antiretroviral therapy (ART) immediately in the international START trial had steeper declines in bone mineral density (BMD) than people randomised to delayed therapy.
In general, tenofovir alafenamide (TAF) is safe, with improvements in bone and kidney health over tenofovir disoproxil fumarate (TDF). However, those with severe kidney disease may not see improvements in kidney health, according to a recent study....